Skip to main content
Premium Trial:

Request an Annual Quote

Genedrive, Partners Win £600K Grant to Develop Plasma Separation Device

NEW YORK (GenomeWeb) – Genedrive announced today that it and two of its collaborators have been awarded a grant worth roughly £600,000 ($795,253) to develop a disposable centrifuge-free plasma separation consumable device.

Genedrive said that it would receive £484,000 of the funding — which is being provided by Innovate UK —  with the remainder going to NHS Tayside and the University of Dundee. With the grant, the partners aim to develop the plasma separation device that can be used with Genedrive's hepatitis C virus assay — a recently CE-IVD marked test that runs on the firm's PCR-based Genedrive portable diagnostic instrument.

"This device will aim to improve the applicability of the Genedrive HCV assay for closer-to-patient settings and would be a significant step forward in positioning the test for true decentralized diagnostics," Genedrive CEO David Budd said in a statement. "Further, the device is anticipated to be independent from the Genedrive platform, opening the opportunity for other diagnostic instruments that need plasma as a starting point for blood-borne viral testing."

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.